On April 1, the FDA approved Foundayo (orforglipron), Eli Lillys once-daily oral GLP-1 receptor agonist for obesity, which is the first oral GLP-1 approved for weight management and the fastest new molecular entity approval since 2002
Microdosing of GLP-1's The Rationale for Microdosing While GLP-1 receptor agonists (GLP-1 RAs) are effective treatments, higher doses can cause gastrointestinal side effects such as nausea and vomiting
Protein malnutrition, though less common, may occur in patients with severe appetite suppression or food aversions, potentially compromising muscle health and function over time
I feel like myself again! The team at Skindale Medspa provided the support and guidance I needed
While some participants did achieve both outcomes simultaneously, an ideal therapeutic goal, this combined outcome was less common than improvement in either condition alone
Tip: Please fill out the form if you or a friend would like more information on glucose monitors
